

PRESS RELEASE

Stockholm, Sweden, 24 October 2017



Sobi™ establishes new leadership structure and appoints Torbjörn Hallberg as General Counsel

[Swedish Orphan Biovitrum AB \(publ\) \(Sobi™\)](#) today announces the establishment of a new leadership structure; Executive Committee, to replace the Executive Leadership Team in its current form. Sobi also announces the appointment of Torbjörn Hallberg as new General Counsel, Head of Legal Affairs.

The Executive Committee is Sobi's decision-making body. Regularly, the Executive Committee will be expanded with key functions, to an Extended Leadership Team.

Sobi's Executive Committee consists of:

Chief Executive Officer – Guido Oelkers

Chief Financial Officer – Mats-Olof Wallin

General Counsel, Head of Legal Affairs – Carin Dahlquist (acting)

Head of EMENARⁱ – Hege Hellström

Head of North America – Rami Levin

Head of Specialty Care – Norbert Oppitz

Head of Medical and Scientific Affairs – Armin Reininger

Head of Haemophilia – Philip Wood

Head of Research & Development, Chief Medical Officer – Milan Zdravkovic

Torbjörn Hallberg joins Sobi from Takeda Pharmaceuticals, where he holds the position as Vice President General Counsel Emerging Markets, heading a legal organisation covering 35 markets. Torbjörn has extensive experience in licensing, mergers and acquisitions. Torbjörn holds a Master of Laws from Lund's University in Sweden and has more than 15 years' experience of in-house counsel roles within pharma. Torbjörn will join Sobi in January 2018.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations

Linda Holmström, Senior Communications Manager
+46 70 873 40 95

linda.holmstrom@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations
+1 347 224 0819, +1 212 579 0506

jorgen.winroth@sobi.com

ⁱ Europe, Middle East, North Africa, Russia